Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Provided By GlobeNewswire
Last update: Jan 14, 2025
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers
Trial marks key milestone in driving pipeline progress
Read more at globenewswire.com0.834
-0.01 (-1.08%)
Find more stocks in the Stock Screener
CNTX Latest News and Analysis
17 days ago - ChartmillUnusual volume stocks in Friday's sessionLet's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.
18 days ago - ChartmillThese stocks that are showing activity before the opening bell on Thursday.The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
